Beta-2-microglobulin (beta 2M) as a tumor marker in nasopharyngeal carcinoma.
The purpose of this study was to assess the clinical value of serum beta-2-microglobulin (beta 2M) in patients with nasopharyngeal carcinoma (NPC). beta 2M levels were assayed in 145 Taiwanese patients with untreated NPC, including 100 squamous cell carcinomas (SCC) and 45 undifferentiated carcinomas. The 145 NPC patients were separated into different subgroups based on the International Union Against Cancer (UICC) TNM classification system. In addition, 50 healthy subjects without any evidence of malignancy or other systemic diseases were included as controls. The results showed that (1) the mean serum, beta 2M level of the 145 NPC patients was higher than that of the 50 healthy controls and (2) the mean serum beta 2M levels of NPC patients who were male, older, with SCC, with higher TNM stages, and with a shorter survival time were higher than those patients who were female, younger, with undifferentiated carcinomas, with lower TNM stages, and with a longer survival time. However, none of the differences were significant. In addition, the overall detecting sensitivity of beta 2M for NPC was only 24.1%, and the detecting sensitivities in NPC patients who were male, older, with SCC, with higher TNM stages, and with a shorter survival time were higher than those of patients who were female, younger, with undifferentiated carcinomas, with lower TNM stages, and with a longer survival time. However, these differences also were not significant. In conclusion, our results suggest the beta 2M may have limited clinical potential as a valuable tumor marker for NPC.